In­ovio shares slide af­ter FDA hits it with a hold on lead PhI­II HPV pro­gram

The FDA has placed In­ovio’s lead ther­a­py on clin­i­cal hold, halt­ing any new work on the pro­gram and putting off a planned start to the Phase III work.

The hold freezes ef­forts on VGX-3100 as the agency looks for “ad­di­tion­al da­ta to sup­port the shelf-life of the new­ly de­signed and man­u­fac­tured dis­pos­able parts of the Cel­lec­tra 5PSP im­munother­a­py de­liv­ery de­vice,” says the biotech $INO.

In­ovio said in a brief state­ment that it now ex­pects to launch the Phase III work in the first half of 2017. Its shares dropped 16% on the news.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER